Advancements in drugs restructured with nanomedicines for multiple myeloma treatment

纳米材料搭载药物治疗多发性骨髓瘤的研究进展

Multiple myeloma(MM)is an incurable malignancy of clonal plasma cells,characterized by high relapse rates and rapid development of drug resistance.The emergence of proteasome inhibitors has dramatically improved the therapeutic effect of MM;however,side effects and drug resistance still negatively affect the survival rate of MM.Nano-medicine has become a promising field for therapeutic innovation owing to its biodegradability and biocompatibility.Nanoparticles(NPs),when combined with MM therapeutic drugs,can reduce side effects,increase treatment efficacy,and alleviate drug resistance,providing a new direction for the treatment of MM.Restructuring drugs with NPs presents an ideal strategy for ongoing studies aimed at more effective therapies.Additionally,clinical nanomedicine research has yielded new opportunities for MM treatment.This review,guided by the development of MM therapeutic drugs,summarizes the past 20 years of research progress and breakthroughs in NP-based systems for treating MM and improving drug targeting ability.

多发性骨髓瘤(MM)是一种不可治愈的克隆性浆细胞恶性肿瘤,具有易复发、易耐药的特点.蛋白酶体抑制剂的出现显著提高了MM的治疗效果;然而,其副作用和耐药性问题仍有待解决.纳米材料由于其良好生物降解性和生物相容性,已成为一个很有前途的治疗领域.纳米颗粒(NPs)搭载MM治疗药物,可减少副作用,提高治疗疗效,缓解耐药性,为MM的治疗提供了新的方向.本文以MM治疗药物的发展为线索,综述了过去20年NPs搭载MM治疗药物的研究进展和突破.